Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Naiqing Ding"'
Autor:
Baorui Liu, Lixia Yu, Mei Rong Zhu, Jie Shao, Shujuan Zhou, Naiqing Ding, Jia Wei, Zhenqing Feng, Hongmei Wang
Publikováno v:
OncoTargets and therapy
Mei Zhu,1– 3,* Hongmei Wang,1,2,* Shujuan Zhou,4,* Jia Wei,2 Naiqing Ding,2 Jie Shao,2 Lixia Yu,2 Zhenqing Feng,5,6 Baorui Liu1,2 1The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanji
Autor:
Ju Yang, Naiqing Ding, Juan Cai, Qin Wang, Qiuping Xu, Baorui Liu, Fangjun Chen, Shiyao Du, Jing Yan, Fanyan Meng, Shujuan Zhou, Jie Shao
Publikováno v:
OncoTargets and Therapy. 12:9757-9765
Background It was previously reported that targeting vascular epithelial growth factor (VEGF)/VEGFR could modulate the antitumor immunity. VEGFR2 inhibitor YN968D1 is a highly selective VEGFR2 inhibitor and was approved for the treatment of late-stag
Autor:
Hanqing Qian, Shujuan Zhou, Xiaoxiao Yu, Baorui Liu, Jia Wei, Shiyao Du, Fanyan Meng, Lifeng Wang, Huizi Sha, Mei Zhu, Naiqing Ding
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPoor infiltration and limited activation of transferred T cells are fundamental factors impeding the development of adoptive cell immunotherapy in solid tumors. A tumor-penetrating peptide iRGD has been widely used to deliver drugs deep int
Autor:
Ju, Yang, Jing, Yan, Jie, Shao, Qiuping, Xu, Fanyan, Meng, Fangjun, Chen, Naiqing, Ding, Shiyao, Du, Shujuan, Zhou, Juan, Cai, Qin, Wang, Baorui, Liu
Publikováno v:
OncoTargets and therapy
Background It was previously reported that targeting vascular epithelial growth factor (VEGF)/VEGFR could modulate the antitumor immunity. VEGFR2 inhibitor YN968D1 is a highly selective VEGFR2 inhibitor and was approved for the treatment of late-stag
Autor:
Liulian Ji, Naiqing Ding, Lianru Zhang, Fangjun Chen, Yan Zhou, Hong Chen, Huizi Sha, Hanqing Qian, Anqing Zhu, Fanyan Meng, Baorui Liu, Qiuping Xu, Lixia Yu
Publikováno v:
International journal of nanomedicine. 13
Hong Chen,1–3,* Huizi Sha,2,* Lianru Zhang,2 Hanqing Qian,2 Fangjun Chen,2 Naiqin Ding,2 Liulian Ji,2 Anqing Zhu,2 Qiuping Xu,2 Fanyan Meng,2 Lixia Yu,2 Yan Zhou,3 Baorui Liu1,2 1The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital Clinical
Autor:
Yao Fu, Zhengyun Zou, Yang Yang, Jie Shao, Huizi Sha, Juan Du, Naiqing Ding, Fangjun Chen, Baorui Liu, Fanyan Meng, Bian Hu, Jia Wei, Xingxu Huang, Shu Su, Lin Li
Publikováno v:
OncoImmunology. 6:e1249558
The successful use of immune cell checkpoint inhibitors PD-1 and PD-L1, over the past 5 y has raised the concern of using immunotherapy to treat various cancers. Epstein-Barr virus-associated gastric cancer (EBVaGC) exhibits high infiltration of lymp